Paeds Vivas · fetal-neonatal-and-perinatal
Respiratory distress syndrome of prematurity — branching viva
Viva on the surfactant-deficiency mechanism, the management ladder, oxygen targeting, surfactant dosing and the prevention of bronchopulmonary dysplasia.
On this page
Study tools
Target exams
Branch 1 — Mechanism and recognition
The examiner opens: "Explain why this infant is in distress." A strong candidate traces surfactant deficiency through raised surface tension, alveolar collapse at end-expiration, low functional residual capacity and compliance, ventilation-perfusion mismatch with hypoxaemia and hypercapnia, and acidosis that further inhibits surfactant and constricts the pulmonary vasculature. The candidate then names expiratory grunting as auto-positive end-expiratory pressure and explains the chest radiograph triad of low volumes, granular opacities and air bronchograms. [1]
References5ShowHide
- [1]Sweet DG European Consensus Guidelines on the Management of Respiratory Distress Syndrome: 2022 Update. Neonatology, 2023.PMID 36863329
- [2]Polin RA Surfactant replacement therapy for preterm and term neonates with respiratory distress. Pediatrics, 2014.PMID 24379227
- [5]Askie LM Association Between Oxygen Saturation Targeting and Death or Disability in Extremely Preterm Infants in the Neonatal Oxygenation Prospective Meta-analysis Collaboration. JAMA, 2018.PMID 29872859
- [7]Morley CJ Nasal CPAP or intubation at birth for very preterm infants. N Engl J Med, 2008.PMID 18272893
- [8]Schmidt B Long-term effects of caffeine therapy for apnea of prematurity. N Engl J Med, 2007.PMID 17989382